105 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
and Gene Strategy & Program Management Office, for Kymriah and the CAR-T pipeline, leading the cross-functional leadership teams for business (marketing
8-K
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
States, where she held a series of roles including serving as Vice-President, Global Oncology Cell and Gene Strategy & Program Management Office. Ms
8-K
EX-10.3
p4rv93nhfcdxg0t
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
0toujw
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
u2cyjiqgy
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
08t3sy hzvbp5x
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
3etgkwosn wqss
30 May 23
Business combination disclosure
4:21pm
8-K
qbuik tmsl
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
bohpj ovu
22 May 23
Business combination disclosure
7:01am
8-K
c2cuyg21c5c4bgo
22 May 23
Other Events
6:59am
8-K
EX-99.1
e168 dfxc
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
xhxal 6yzbymlcsxvpyf
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
tougdjgv 1f
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm